| |
FDA has approved Abraxane for the treatment of metastatic breast cancer. This drug is an improved version of Taxol, which is currently used for the treatment of metastatic breast cancer. This new drug is an improved version of Taxol. Abraxane is manufactured by American Pharma and is the first approval for the group of drugs called, protein-bound particle drugs. These drugs are free of toxic solvents which may cause problems with the administration of chemotherapy drugs. Abraxane, consisting only of albumin-bound paclitaxel nanoparticles, and is free of toxic solvents. Abraxane is an step forward in the treatment of breast cancer. The pivotal clinical trial that lead to the FDA approval has demonstrated that Abraxane had superior response rate when compared to Taxol in patients with metastatic breast cancer. The study consisted of 460 patients with metastatic breast cancer that showed Abraxane has a superior response rate and has almost double reconciled target lesion response rate when compared with Taxol. FDA approval for Abraxane is for those patients who had treatment failures to combination chemotherapy for metastatic breast cancer or those whos disease has relapsed within 6 months of adjuvant chemotherapy. Patients should have been previously treated with anthracyclin group of drugs (like doxorubicin or epirubicin) or should have contra-indication for these drugs before starting on Abraxane.
Read more about abraxane:
Abraxane, the new generation paclitaxel
|
|
|
|
|
|
|
|
|
